2,5- bis(3,4,5- trimethoxyphenyl)tetrahydrofuran

orally active & competitive receptor antagonist of platelet activating factor; structure given in first source

Also Known As:

L 652731; L-652,731; Furan, tetrahydro-2,5-bis(3,4,5-trimethoxyphenyl)-, trans-

Networked: 14 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Furans: 85
    - 2,5-bis(3,4,5-trimethoxyphenyl)tetrahydrofuran: 14

Related Diseases

1.	Leukopenia 01/03/1991 - "In addition, L-652,731 completely restored macrophage phagocytosis, partially improved macrophage killing and significantly inhibited leukopenia. " 12/01/1986 - "dose of L-652,731 inhibited PAF-induced leukopenia and neutropenia by 96 and 73%, respectively. " 09/01/1988 - "Moreover, the anaphylactic bronchoconstriction, thrombocytopenia, leukopenia (actively sensitized) and hemoconcentration were not inhibited by CV-3988 (10 mg/kg, i.v.) and L-652,731 (3 mg/kg, i.v.). "
2.	Inflammation (Inflammations) 10/01/1987 - "A study of PAF-induced ocular inflammation in the rat and its inhibition by the PAF antagonist, L-652,731." 10/01/1987 - "In contrast, the PAF-induced inflammation was blocked by the oral administration of the PAF receptor antagonist, L-652,731, a dose as low as 5 mg kg-1 eliciting a significant inhibition. "
3.	Proteinuria 05/01/1989 - "The protective effect of L-652,731 on proteinuria in the autologous phase and on glomerular filtration rate in both phases was superior to that of FCE-22178. " 02/01/1988 - "PAF-induced proteinuria was prevented by L-652,731, a specific PAF receptor antagonist, suggesting that PAF's effect on glomerular permeability to proteins is likely to be related to its biologic activity. " 01/01/1990 - "In this context we have documented that the PAF receptor antagonist L-652,731 markedly prevented renal function deterioration and development of proteinuria, and reduced glomerular hypercellularity, fibrin deposition in Bowman's space, and tubular cast formation in a rabbit model of nephrotoxic serum nephritis. "
4.	Neutropenia 12/01/1986 - "dose of L-652,731 inhibited PAF-induced leukopenia and neutropenia by 96 and 73%, respectively. " 06/15/1986 - "L-652,731 when orally administered to rats (20 mg/kg, 1.5 hr before PAF infusion) inhibited PAF-induced hypotension (69%), extravasation (76%), vascular lysosomal hydrolase release (79%), and neutropenia (73%). " 09/01/1987 - "L-652,731 at a dose of 8 mg/kg blocked completely the neutropenia, thrombocytopenia, thromboxane synthesis, pulmonary hypertension and hypoxia induced by 5 micrograms of PAF, but this protective effect was not observed in animals infused with ZAP. "
5.	Thrombocytopenia (Thrombopenia) 09/01/1988 - "Moreover, the anaphylactic bronchoconstriction, thrombocytopenia, leukopenia (actively sensitized) and hemoconcentration were not inhibited by CV-3988 (10 mg/kg, i.v.) and L-652,731 (3 mg/kg, i.v.). " 09/01/1987 - "L-652,731 at a dose of 8 mg/kg blocked completely the neutropenia, thrombocytopenia, thromboxane synthesis, pulmonary hypertension and hypoxia induced by 5 micrograms of PAF, but this protective effect was not observed in animals infused with ZAP. "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Fibrin
3.	CV 3988
4.	Thromboxanes
5.	Proteins (Proteins, Gene)
6.	Indomethacin (Indometacin)
7.	Hydrolases
8.	Cyclophosphamide (Cytoxan)
9.	Complement System Proteins (Complement)
10.	Antigen-Antibody Complex (Immune Complex)

Related Therapies and Procedures

1.	Controlled Hypotension
2.	Oral Administration